Atsushi Nohara1, Hayato Tada2, Masatsune Ogura3, Sachiko Okazaki4, Koh Ono5, Hitoshi Shimano6, Hiroyuki Daida7, Kazushige Dobashi8, Toshio Hayashi9, Mika Hori10, Kota Matsuki11, Tetsuo Minamino12, Shinji Yokoyama13, Mariko Harada-Shiba14, on behalf of the Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan
1Department of Clinical Genetics, Ishikawa Prefectural Central Hospital, 2Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 3Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 4Division for Health Service Promotion, The University of Tokyo, 5Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 6Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine University of Tsukuba, 7Faculty of Health Science, Juntendo University, Juntendo University Graduate School of Medicine, 8Department of Pediatrics, School of Medicine, University of Yamanashi, 9School of Health Sciences, Nagoya University Graduate School of Medicine, 10Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University, 11Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 12Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, 13Institute for Biological Functions, Chubu University, 14Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute
Journal of Atherosclerosis and Thrombosis 28(7): 665-678, 2021.